Clinical Trial Search

Primary: Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90…

Primary: Local Control Rate — 1 Participants

Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235

Primary: Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or…

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Progression-free Survival — 5.7 months

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: One Year Survival Rate — 0.502 proportion of patients

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Tumor Response — 5; 3 Participants

Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants

Primary: Conversion Rate of Inoperable to Operable

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)

Primary: Overall Survival Rate at 6 Months — 58 percentage of participants

Primary: Progression-free Survival at 6 Months — 82 percentage of participants

Primary: Percentage of Participants With Adverse Events (AEs) — 78.8 percentage of participants